Arena Pharmaceuticals

We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. Our internally discovered drug for chronic weight management, BELVIQ ® (lorcaserin HCl), was approved by the FDA for marketing in the United States to adults who are overweight with a comorbidity or obese, and was made available to patients by our collaborator, Eisai, by prescription in June 2013. In February 2015, BELVIQ was also approved for weight management in South Korea and will be marketed by our collaborator, Ildong.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1977
Size (employees)
228 (est)
Arena Pharmaceuticals was founded in 1977 and is headquartered in San Diego, US

Arena Pharmaceuticals Office Locations

Arena Pharmaceuticals has offices in San Diego and Zofingen
San Diego, US (HQ)
6154 Nancy Ridge Drive
Zofingen, CH
4 Untere Brühlstrasse

Arena Pharmaceuticals Data and Metrics

Arena Pharmaceuticals Financial Metrics

Arena Pharmaceuticals's revenue was reported to be $124 m in 2016
$, USD

Revenue (Y, 2016)

124 m

Revenue growth (Y, 2015 - Y, 2016), %

223%

Gross profit (Y, 2016)

114.7 m

Gross profit margin (Y, 2016), %

93%

Net income (Y, 2016)

(22.9 m)

EBIT (Y, 2016)

(17.1 m)

Market capitalization (23-Jun-2017)

472.3 m

Closing share price (23-Jun-2017)

16.2

Cash (31-Dec-2016)

90.7 m
Arena Pharmaceuticals's current market capitalization is $472.3 m.
$, USDFY, 2013FY, 2014FY, 2015Y, 2016

Revenue

81.4 m37 m38.3 m124 m

Revenue growth, %

(55%)4%223%

Cost of goods sold

1.8 m6.4 m8.6 m9.3 m

Gross profit

79.6 m30.6 m29.7 m114.7 m

Gross profit Margin, %

98%83%78%93%

Operating expense total

104.3 m135.9 m132.9 m141.1 m

EBIT

(22.9 m)(105.3 m)(103.2 m)(17.1 m)

EBIT margin, %

(28%)(285%)(269%)(14%)

Interest expense

7.1 m6.9 m6.8 m6.5 m

Interest income

89 k83 k158 k290 k

Net Income

(19.4 m)(60.5 m)(108 m)(22.9 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

221.9 m163.2 m156.2 m90.7 m

Accounts Receivable

10.6 m3.7 m4.9 m20.2 m

Inventories

3.6 m4.1 m4.2 m2.3 m

Current Assets

248.8 m181.9 m174.8 m119.9 m

Total Assets

339.8 m276.4 m256.8 m169 m

Current Liabilities

70.7 m67.4 m49.9 m63.9 m

Additional Paid-in Capital

1.3 b1.3 b1.4 b1.4 b

Retained Earnings

(1.2 b)(1.3 b)(1.4 b)(1.4 b)

Total Equity

91.9 m47.3 m53.5 m40.4 m

Financial Leverage

3.7 x5.8 x4.8 x4.2 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(19.4 m)(60.5 m)(108 m)(22.9 m)

Depreciation and Amortization

7.7 m8.7 m9.8 m9.1 m

Accounts Receivable

(4.5 m)6.4 m(1.4 m)(16 m)

Inventories

(6.1 m)870 k1.9 m3.2 m

Cash From Operating Activities

72.8 m(101.4 m)(98.1 m)(62.1 m)

Cash From Investing Activities

(8.7 m)40.9 m(8.2 m)(750 k)

Cash From Financing Activities

1.7 m3.2 m101.1 m(2.3 m)

Interest Paid

7 m6.8 m6.6 m6.3 m
Y, 2016

Financial Leverage

4.2 x

Arena Pharmaceuticals Market Value History

Arena Pharmaceuticals Company Life and Culture

You may also be interested in